Global Overactive Bladder (OAB) Therapeutics Industry

Sep 08, 2011, 06:15 ET from Reportlinker

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Overactive Bladder (OAB) Therapeutics Industry

http://www.reportlinker.com/p0611038/Global-Overactive-Bladder-OAB-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 34 companies including many key and niche players such as Allergan, Inc., Antares Pharma, Inc., Apogepha Arzneimittel GmbH, Astellas Pharma, Inc., Auxilium Pharmaceuticals, Inc., Kissei Pharmaceuticals Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pfizer, Inc., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

2. INDUSTRY OVERVIEW 4

Outlook 4

Current & Future Analysis 4

Underdiagnosis - A Key Market Deterrent 4

Increasing Awareness- A Key to Success 5

Reaching Out to Urologists - A Key Strategy 5

Improved OAB Medications to Drive Growth 5

Ageing Population Reflect Significant market Opportunity 6

Table 1: Ageing (65+) Demographics as % of Total Population

by Country (2000, 2010, 2025) (includes corresponding

Graph/Chart) 6

Table 2: Prevalence (%) of Overactive Bladder Symptoms by Age

(includes corresponding Graph/Chart) 7

Meager OAB Developmental Pipeline Deters Growth Prospects 7

Generics Stalls Revenues 7

3. COMPETITION 8

The Branded Drugs Landscape 8

Table 3: Sales of Major Overactive Bladder Drugs (2009) (In

US$ Million) (includes corresponding Graph/Chart) 8

Review of Select Available Drugs 9

Detrol and Detrol LA (Tolterodine tartrate) 9

VESIcare® (solifenacin succinate) 9

SANCTURA® (trospium chloride) 9

Toviaz® (fesoterodine fumarate) 9

Enablex® (Darifenacin) 9

Ditropan and Ditropan XL (Oxybutynin chloride) 9

Oxytrol (Oxybutynin Patch) 10

The OAB Brand Matrix 10

4. URINARY INCONTINENCE - AN INSIGHT 11

How Does Normal Urinary Bladder Function? 11

What is Urinary Incontinence? 11

Male Incontinence 11

Women More Prone to Incontinency than Men 12

Incontinence Among Children 12

Types of Urinary Incontinence 12

Stress Incontinence 12

Urge Incontinence 13

Functional Incontinence 13

Overflow Incontinence 13

Mixed Incontinence 14

Reflex Incontinence 14

Transient Incontinence 14

Traumatic Incontinence 14

5. OVERACTIVE BLADDER 15

Definition 15

Types 15

By Incontinence 15

Overactive Bladder Dry 15

Overactive Bladder Wet 15

By Symptomatic Causes 15

Neurogenic OAB 15

Idiopathic OAB 16

Etiology 16

Symptoms 16

Impact of Overactive Bladder on Quality of Life 16

Diagnosis 17

Measurement of Postvoid Residual Urine 17

Cystoscopy 17

Uroflowmetry 18

Cystometry 18

Electromyography 18

Video Urodynamics 18

Treatment Options 18

Behavioral Remedies 18

Pharmacotherapy 19

Anticholinergic agents 19

Other Therapeutic Approaches 19

Device Therapy 19

Device Therapies in Men 19

Device and Minimally-Invasive Therapies in Women 20

Neuromodulation 20

Vaginal Devices 20

Collagen Injections 20

Retropubic Suspension 20

Sling Procedure 20

Midurethral Slings 21

Dietary Changes and Alternative Medicines 21

6. PRODUCT LAUNCHES/INTRODUCTIONS 22

Dr. Reddy's Laboratories Launches Bispec 22

Watson Pharmaceuticals Introduces GELNIQUE™ (oxybutynin

chloride) Gel 10% 22

Pfizer Launches TOVIAZ® 22

7. RECENT INDUSTRY ACTIVITY 24

Warner Chilcott Purchases US Rights of Enablex from Novartis 24

Serenity Pharmaceuticals and Allergan Enter Into Agreement 24

Astellas Pharma Applies for Approval of YM178 in Japan 24

Kyorin Pharmaceutical and Ono Pharmaceutical Independently

File NDA 24

Endo Pharmaceuticals Purchases Indevus Pharmaceuticals 25

Allergan Signs Co-promotion Agreement with Quintiles

Transnational 25

P&G Inks Agreement with Warner Chilcott 25

Astellas Pharma to Introduce Vesicare in China 26

Kyorin Pharmaceutical Inks Licensing Agreement with Eisai 26

Astellas Pharma Unveils Expansion Plans in India 26

Speciality European Pharma Obtains Distribution Rights to

Regurin and Regurin XL 27

Toray and Taiho Pharmaceutical Enter into Alliance 27

Astellas Pharma Files Patent Infringement Lawsuit against Teva

Pharmaceutical 27

Indevus Pharmaceuticals Inks License Agreement with Allergan 27

Asahi Kasei Obtains Intellectual Property Rights of Flivas

from Roche Diagnostics 28

8. FOCUS ON SELECT GLOBAL PLAYERS 29

Allergan, Inc. (US) 29

Antares Pharma, Inc. (US) 29

Apogepha Arzneimittel GmbH (Germany) 29

Astellas Pharma, Inc. (Japan) 30

Auxilium Pharmaceuticals, Inc. (US) 30

Kissei Pharmaceuticals Co., Ltd. (Japan) 30

KYORIN Pharmaceutical Co., Ltd. (Japan) 30

Novartis AG (Switzerland) 31

Ono Pharmaceutical Co., Ltd. (Japan) 31

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (USA) 31

Pfizer, Inc. (US) 32

SALVAT Biotech (Spain) 32

Sepracor Pharmaceuticals, Inc. (Canada) 32

Watson Pharmaceuticals, Inc. (US) 33

9. GLOBAL MARKET PERSPECTIVE 34

Table 4: World Recent Past, Current & Future Market Analysis

for Overactive Bladder Therapeutics by Country/Geographic

Region - US, Japan, Europe and Rest of World Markets

Independently Analyzed with Annual Revenues in US$ Million for

Years 2009 through 2017 (includes corresponding Graph/Chart) 34

Table 5: World Historic Review for Overactive Bladder

Therapeutics by Country/Geographic Region - US, Japan, Europe,

and Rest of World Markets Independently Analyzed with Annual

Consumption in Thousand Metric Tons for Years 2003 through

2008 (includes corresponding Graph/Chart) 35

Table 6: World 15-Year Perspective for Overactive Bladder

Therapeutics by Geographic Region - Percentage Breakdown of

Dollar Sales for US and Rest of World Markets for Years 2003,

2010 & 2017 (includes corresponding Graph/Chart) 36

10. THE UNITED STATES 37

A.Market Analysis 37

Overview 37

Competition 37

Table 7: US Market for Overactive Bladder Therapeutics

(2009): Percentage Share Breakdown by Drugs- Detrol/Detrol

LA, Vesicare, Enablex, Generic Oxybutynin,

Sanctura/Sanctura XR and Others (includes corresponding

Graph/Chart) 37

Table 8: US Market for OAB Drugs: Prescription Share for

Oral and Transdermal Medications 38

Patent Expiry of Select Overactive Bladder Drugs 38

Strategic Corporate Developments 38

Key Player Review 40

B.Market Analytics 42

Table 9: The United States Recent Past, Current & Future

Market Analysis for Overactive Bladder Therapeutics with

Annual Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 42

Table 10: The United States Historic Review for Overactive

Bladder Therapeutics with Annual Revenues in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 43

11. JAPAN 44

A.Market Analysis 44

Strategic Corporate Developments 44

Key Player Review 44

B.Market Analytics 46

Table 11: Japanese Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 46

Table 12: Japanese Historic Review for Overactive Bladder

Therapeutics with Annual Revenues in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 47

12. EUROPE 48

A.Market Analysis 48

Key Player Review 48

B.Market Analytics 49

Table 13: European Past, Current & Future Market Analysis

for Overactive Bladder Therapeutics by Country/Geographic

Region - France, Germany, Italy, UK, and Rest of Europe

Markets Independently Analyzed with Annual Revenues in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 49

Table 14: European Historic Review for Overactive Bladder

Therapeutics by Country/Geographic Region - France, Germany,

Italy, UK, and Rest of Europe Markets Independently Analyzed

with Annual Revenues in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) 50

Table 15: European 15-Year Perspective for Overactive

Bladder Therapeutics by Country/Geographic Region -

Percentage Breakdown of Dollar Sales for France, Germany,

Italy, UK, and Rest of Europe Markets for Years 2003, 2010 &

2017 (includes corresponding Graph/Chart) 51

12a. FRANCE 52

Market Analysis 52

Table 16: French Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 52

Table 17: French Historic Review for Overactive Bladder

Therapeutics with Annual Revenues in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 52

12b. GERMANY 53

Market Analysis 53

Table 18: German Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 53

Table 19: German Historic Review for Overactive Bladder

Therapeutics with Annual Revenues in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 53

12c. ITALY 54

Market Analysis 54

Table 20: Italian Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 54

Table 21: Italian Historic Review for Overactive Bladder

Therapeutics with Annual Revenues in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 54

12d. THE UNITED KINGDOM 55

Market Analysis 55

Table 22: The UK Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 55

Table 23: The UK Historic Review for Overactive Bladder

Therapeutics with Annual Revenues in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) 55

12e. REST OF EUROPE 56

Market Analysis 56

Table 24: Rest of Europe Recent Past, Current & Future

Market Analysis for Overactive Bladder Therapeutics with

Annual Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 56

Table 25: Rest of Europe Historic Review for Overactive

Bladder Therapeutics with Annual Revenues in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 57

13. REST OF WORLD 58

A.Market Analysis 58

Strategic Corporate Developments 58

B.Market Analytics 59

Table 26: Rest of World Recent Past, Current & Future Market

Analysis for Overactive Bladder Therapeutics with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 59

Table 27: Rest of World Historic Review for Overactive

Bladder Therapeutics with Annual Revenues in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) 60

COMPETITIVE LANDSCAPE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 39)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 16

Canada 2

Japan 9

Europe 10

Germany 3

The United Kingdom 2

Italy 2

Spain 1

Rest of Europe 2

Asia-Pacific (Excluding Japan) 2

------------------------------------------

To order this report:

Drug and Medication Industry: Global Overactive Bladder (OAB) Therapeutics Industry

Drug and Medication Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com